These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 11488086

  • 1. [Anti-TNF alpha in rheumatoid arthritis].
    Schreiber S, Sternon J.
    Rev Med Brux; 2001 Jun; 22(3):174-80. PubMed ID: 11488086
    [Abstract] [Full Text] [Related]

  • 2. [How I treat...rheumatoid arthritis. The arrival of a new therapeutic era: anti-tumor necrosis factor alpha antibodies].
    Kaiser MJ, Malaise MG.
    Rev Med Liege; 2002 Aug; 57(8):486-92. PubMed ID: 12405019
    [Abstract] [Full Text] [Related]

  • 3. [Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].
    Tijhuis GJ, van de Putte LB, Breedveld FC.
    Ned Tijdschr Geneeskd; 2001 Sep 29; 145(39):1880-5. PubMed ID: 11605312
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs].
    Bombardieri S, Ferraccioli G, Ferri C, Galeazzi M, Lapadula G, Cerinic MM, Montecucco C, Triolo G, Trotta F, Valentini G.
    Reumatismo; 2009 Sep 29; 61 Suppl 1():1-23. PubMed ID: 19999184
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Tumor necrosis factor inactivation in the management of rheumatoid arthritis.
    Baumgartner SW.
    South Med J; 2000 Aug 29; 93(8):753-9. PubMed ID: 10963503
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Tumour necrosis factor-alpha blockers in rheumatoid arthritis: review of the clinical experience.
    Richard-Miceli C, Dougados M.
    BioDrugs; 2001 Aug 29; 15(4):251-9. PubMed ID: 11437690
    [Abstract] [Full Text] [Related]

  • 11. [Value of anti-TNF-alpha molecules in inflammatory and infectious diseases].
    Fautrel B, Cherin P.
    Rev Med Interne; 2000 Oct 29; 21(10):872-88. PubMed ID: 11075396
    [Abstract] [Full Text] [Related]

  • 12. Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-alpha blocking agents.
    Halvorsen EH, Haavardsholm EA, Pollmann S, Boonen A, van der Heijde D, Kvien TK, Molberg Ø.
    Ann Rheum Dis; 2009 Feb 29; 68(2):249-52. PubMed ID: 18723564
    [Abstract] [Full Text] [Related]

  • 13. Treatment of rheumatoid arthritis by TNF-blocking agents.
    Graninger W, Smolen J.
    Int Arch Allergy Immunol; 2002 Jan 29; 127(1):10-4. PubMed ID: 11893849
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis.
    Nuijten MJ, Engelfriet P, Duijn K, Bruijn G, Wierz D, Koopmanschap M.
    Pharmacoeconomics; 2001 Jan 29; 19(10):1051-64. PubMed ID: 11735673
    [Abstract] [Full Text] [Related]

  • 16. [Innovative therapeutic options for psoriatic arthritis: TNFalpha inhibitors].
    Lehnen M, Goos M, Dissemond J.
    Dtsch Med Wochenschr; 2004 Mar 19; 129(12):634-8. PubMed ID: 15011134
    [No Abstract] [Full Text] [Related]

  • 17. [Effectiveness of TNF antagonists in routine clinical practice and costs].
    Prokes M.
    Vnitr Lek; 2009 Jan 19; 55(1):45-53. PubMed ID: 19227955
    [Abstract] [Full Text] [Related]

  • 18. Anti-tumour necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland.
    Cairns AP, Taggart AJ.
    Ulster Med J; 2002 Nov 19; 71(2):101-5. PubMed ID: 12513005
    [Abstract] [Full Text] [Related]

  • 19. [Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies].
    González-Gay MA, Agudo M.
    Med Clin (Barc); 2010 May 22; 134(15):684-5. PubMed ID: 20176386
    [No Abstract] [Full Text] [Related]

  • 20. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis.
    Barton P, Jobanputra P, Wilson J, Bryan S, Burls A.
    Health Technol Assess; 2004 Mar 22; 8(11):iii, 1-91. PubMed ID: 14982655
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.